drugset
drugset / Trial / NCT02266147

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

NCT02266147 ↗

Phase 1/2 Terminated 29 enrolled Dynavax Technologies Corporation
SequentialOpen-labelTreatment

Summary

To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.

Timeline

Start
2014-10
Primary completion
2017-04
Completion
2017-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelitolimod Oligonucleotide (other) 1 mg/ml Other
Subject Nelitolimod Oligonucleotide (other) 2 mg/ml Other
Subject Nelitolimod Oligonucleotide (other) 4 mg/ml Other
Subject Nelitolimod Oligonucleotide (other) 8 mg/ml Other

Indications

B-cell neoplasm